{
    "organizations": [],
    "uuid": "0b02ced9c9ce4a9f4f5284c0c715514632505746",
    "author": "",
    "url": "https://www.reuters.com/article/brief-grifols-receives-fda-approval-for/brief-grifols-receives-fda-approval-for-new-formulation-of-its-rabies-virus-treatment-idUSASB0C493",
    "ord_in_thread": 0,
    "title": "BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 6, 2018 / 2:58 PM / Updated 4 minutes ago BRIEF-Grifols Receives FDA Approval For New Formulation Of Its Rabies Virus Treatment Reuters Staff 1 Min Read \nFeb 6 (Reuters) - Grifols SA: \n* GRIFOLS HYPERRABÂ® (RABIES IMMUNE GLOBULIN) 300 IU/ML RECEIVES FDA APPROVAL TO TREAT PATIENTS EXPOSED TO RABIES VIRUS INFECTION Source text for Eikon: Further company coverage: (Gdynia Newsroom)",
    "published": "2018-02-06T16:57:00.000+02:00",
    "crawled": "2018-02-06T17:04:17.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "receives",
        "fda",
        "approval",
        "new",
        "formulation",
        "rabies",
        "virus",
        "treatment",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "grifols",
        "sa",
        "grifols",
        "rabies",
        "immune",
        "globulin",
        "receives",
        "fda",
        "approval",
        "treat",
        "patient",
        "exposed",
        "rabies",
        "virus",
        "infection",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}